Clinafloxacin
| パラメータ | 仕様 |
|---|---|
| 製品名 | Clinafloxacin |
| CAS番号 | 105956-97-6 |
| 分子式 | C17H17ClF2N4O3 |
| 分子量 | 398.79 g/mol |
| 外観 | 白色からオフホワイトの結晶性粉末 |
| 分析(HPLC) | ≥98.0% |
| 溶解度 | Slightly soluble in water; soluble in aqueous acid and alkali |
お困りですか? 弊社チームまでお問い合わせください

同義語: 7-(3-Amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, Clinafloxacin, CI-960, PD 127391, 105956-97-6
Clinafloxacin is a fluoroquinolone antibacterial API supplied as a white to off-white crystalline powder. It is manufactured through multi-step organic synthesis and is available in research and bulk quantities for pharmaceutical and veterinary formulation.
As a fourth-generation fluoroquinolone, clinafloxacin exhibits broad-spectrum activity against both Gram-positive and Gram-negative bacteria, including many resistant strains. The product is typically offered at ≥98% purity by HPLC, with residual solvents and impurities controlled to meet customer specifications.
Formulators use clinafloxacin in oral and injectable dosage forms, as well as in topical preparations and veterinary medicines. Its solubility profile allows for formulation in aqueous solutions and suspensions, and it is often chosen for development projects targeting difficult-to-treat infections.
Clinafloxacin fits into oral solid dosage forms such as tablets and capsules, where its high potency allows for lower drug loading. In liquid formulations, it can be dissolved in slightly acidic aqueous media or suspended in syrups for pediatric or veterinary use. Topical gels and ointments benefit from its broad-spectrum activity, particularly in wound care and dermatological infections. The compound is also a reference standard in analytical laboratories and a starting point for structure-activity relationship studies in antibacterial discovery.
Clinafloxacin is produced via a convergent synthesis starting from commercially available fluoroquinolone intermediates. The process involves cyclization, substitution, and purification steps under cGMP conditions. Final crystallization yields a crystalline powder that is milled and sieved to a consistent particle size. Production runs are scaled to meet both small-scale research needs and commercial demand, with batch sizes ranging from kilograms to metric tons.
send us your specification for a quotation.